Daniel Oren, Matan Uriel, Cathrine M Moeller, Andrea Fernandez Valledor, Ersilia M DeFilippis, Dor Lotan, Paolo C Colombo, Melana Yuzefpolskaya, Veli K Topkara, Kevin J Clerkin, Jayant K Raikhelkar, Justin A Fried, David Kyung Taek Oh, David Bae, Eddie Lin, Kleanthis Theodoropoulos, Yoshifumi Naka, Koji Takeda, Jason Choe, Douglas L Jennings, David Majure, Farhana Latif, Gabriel Sayer, Nir Uriel
BACKGROUND: Belatacept (BTC), a fusion protein, selectively inhibits T-cell co-stimulation by binding to the CD80 and CD86 receptors on antigen-presenting cells (APCs) and has been used as immunosuppression in adult renal transplant recipients. However, data regarding its use in heart transplant (HT) recipients are limited. This retrospective cohort study aimed to delineate BTC's application in HT, focusing on efficacy, safety, and associated complications at a high-volume HT center. METHODS: A retrospective cohort study was conducted of patients who underwent HT between January 2017 and December 2021 and subsequently received BTC as part of their immunosuppressive regimen...
March 2024: Clinical Transplantation